Send to

Choose Destination
Br J Haematol. 2019 May 24. doi: 10.1111/bjh.15969. [Epub ahead of print]

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Author information

University of Chicago Medical Center, Chicago, IL, USA.
Weill Cornell Medical College, New York, NY, USA.
Department of Medicine, Division of Hematology/Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Tisch Cancer Institute/Multiple Myeloma Program, Mount Sinai School of Medicine, New York, NY, USA.
Mayo Clinic, Phoenix, AZ, and International Myeloma Foundation, Los Angeles, CA, USA.
Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.


Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non-clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I dose-escalation trial of twice-weekly selinexor in combination with carfilzomib and dexamethasone (SKd) to determine maximum tolerated dose in patients with RRMM (N = 21), with an expansion cohort to assess activity in carfilzomib-refractory disease and identify a recommended phase II dose (RP2D). During dose escalation, there was one dose-limiting toxicity (cardiac failure). The RP2D of twice-weekly SKd was selinexor 60 mg, carfilzomib 20/27 mg/m2 and dexamethasone 20 mg. The most common grade 3/4 treatment-emergent adverse events included thrombocytopenia (71%), anaemia (33%), lymphopenia (33%), neutropenia (33%) and infections (24%). Rates of ≥minimal response, ≥partial response and very good partial response were 71%, 48% and 14%, respectively; similar response outcomes were observed for dual-class refractory (PI and immunomodulatory drug)/quad-exposed (carfilzomib, bortezomib, lenalidomide and pomalidomide) patients (n = 17), and patients refractory to carfilzomib in last line of therapy (n = 13). Median progression-free survival was 3·7 months, and overall survival was 22·4 months in the overall population. SKd was tolerable and re-established disease control in RRMM patients, including carfilzomib-refractory patients. Registered at (NCT02199665).


carfilzomib; dexamethasone; relapsed/refractory multiple myeloma; selinexor


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center